We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.
ARTICLE · 30 OCTOBER 2015
AstraZeneca And Ranbaxy Avoid Heartburn Of A New Antitrust Trial
McDermott Will & Emery
In order to succeed, the plaintiffs had to prove the no-AG clauses caused "an 'antitrust injury'—a real-world impact on the relevant market from the alleged monopolistic practice or practices."
United StatesIntellectual Property








